[en] Metalloproteinases and serine proteinases have been associated with tumor invasion and formation of metastasis which represent the major obstacles to cancer cure. The contribution of proteinases in these processes was initially thought to be the destruction of extracellular matrices. However, recent evidence suggests that they mainly affect tumor growth rather than invasion. Proteinases can indeed generate active matrix protein fragments, influence the release, the activation and the bioavailability of growth factors, and consequently modulate tumor cell growth, apoptosis and angiogenesis. Additionally, proteinases, their receptors and/or inhibitors can be directly involved in cell migration and in the processing or shedding of cell surface proteins. Further elucidation of the functions of proteinases is essential for the development of novel anticancer strategies.
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Noël, Agnès ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biologie cellulaire et moléculaire appliquée à l'homme
Gilles, Christine ; Université de Liège - ULiège > Département des sciences cliniques > Labo de biologie des tumeurs et du développement
Bajou, Khalid ; Université de Liège - ULiège > Département des sciences de la vie > Biologie et génétique moléculaire
Devy, L.
Kebers, F.
Lewalle, J. M.
Maquoi, Erik ; Université de Liège - ULiège > Département des sciences cliniques > Labo de biologie des tumeurs et du développement
Munaut, Carine ; Université de Liège - ULiège > Département des sciences cliniques > Labo de biologie des tumeurs et du développement
Remacle, A.
Foidart, Jean-Michel ; Université de Liège - ULiège > Département des sciences cliniques > Gynécologie - Obstétrique
Twining SS: Regulation of proteolytic activity in tissues. Crit Rev Biochem Mol Biol 1994;29:315-383.
Andreasen PA, Kjoller L, Christensen L, Duffy MJ: The urokinase-type plasminogen activator system in cancer metastasis: A review. Int J Cancer 1997;72:1-22.
Chapman HA, Riese RJ, Shi G-P: Emerging roles for cysteine proteases in human biology. Annu Rev Physiol 1997;59:63-88.
Murphy G, Knäuper V: Relating matrix metalloproteinase structure to function: Why the 'hemopexin' domain? Matrix Biol 1997;15:511-518.
Kute TE, Grøndahl-Hansen J, Shao S-M, Long R, Russell G, Brünner N: Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence. Breast Cancer Res Treat 1998;47:9-16.
Chenard MP, O'Siorain L, Shering S, Rouyer N, Lutz Y, Wolf C, Basset P, Bellocq JP, Duffy MJ: High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma. Int J Cancer (Pred Oncol) 1996;69:448-451.
Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, De Vos R, van den Oord JJ, Collen D, Mulligan RC: Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994;368:419-423.
Itoh T, Ikeda T, Gomi H, Nakao S, Suzuki T, Itohara S: Unaltered secretion of β-amyloid precursor protein in gelatinase A (matrix metalloproteinase 2)-deficient mice. J Biol Chem 1997;272:22389-22392.
Masson R, Lefèbvre O, Noël A, Chenard MP, Wendung C, Kebers F, Lemeur M, Dierich A, Foidart JM, Basset P, Rio MC: In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J Cell Biol 1998;100:1535-1541.
Shipley JM, Wesselschmidt RL, Kobayashi DK, Ley TJ, Shapiro SD: Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc Natl Acad Sci USA 1996;93:3942-3946.
Wilson CL, Heppner KJ, Labosky PA, Hogan BLM, Matrisian LM: Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci USA 1997;94:1402-1407.
Vu TH, Shipley MJ, Bergers G, Berger JE, Helms JA, Hanahan D, Shapiro SD, Senior RM, Werb Z: MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 1998;93:411-422.
DeClerck YA, Imren S, Montgomery AMP, Mueller BM, Reisfeld RA, Laug WE: Proteases and protease inhibitors in tumor progression; in Church et al. (eds): Chemistry and Biology of Serpins. New York, Plenum Press, 1997, pp 89-97.
Keppler D, Sameni M, Moin K, Mikkelsen T, Diglio CA, Sloane BF: Tumor progression and angiogenesis: Cathepsin B & Co. Biochem Cell Biol 1996;74:799-810.
Basset P, Okada O, Chenard MP, Kannan R, Stoll I, Anglard P, Bellocq JP, Rio MC: Matrix metalloproteinases as stromal effectors of human carcinoma progression: Therapeutic implications. Matrix Biol 1997;15:535-541.
Rudolph-Owen LA, Matrisian LM: Matrix metalloproteinases in remodeling of the normal and neoplastic mammary gland. J Mam Gland Biol Neoplasia 1998;3:177-190.
Stöcker W, Bode W: Structural features of a superfamily of zinc-endopeptidases: The metzincins. Curr Opin Struct Biol 1995;5:383-390.
Seiki M: Membrane type-matrix metalloproteinase and tumor invasion. Curr Top Microbiol Immunol 1996;213:23-32.
Springman EB, Angleton EL, Birkedal-Hansen H, Van Wart HE: Multiple modes of activation of latent human fibroblast collagenase: Evidence for the role of a Cys73 active-size zinc complex in latency and a 'cysteine switch' mechanism for activation. Proc Natl Acad Sci USA 1990;87:364-368.
Edwards DR, Beaudry PP, Laing TD, Kowal V, Leco KJ, Leco PA, Lim MS: The roles of tissue inhibitors of metalloproteinases in tissue remodeling and cell growth. Int J Obesity 1996;20:S9-S15.
Wang M, Liu YE, Greene J, Sheng S, Fuchs A, Rosen EM, Shi YE: Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4. Oncogene 1997;14:2767-2774.
Conese M, Blasi F: Urokinase/urokinase receptor system: Internalization/degradation of urokinase-serpin complexes: Mechanism and regulation. Biol Chem Hoppe-Seyler 1995;376:143-155.
Gensberg K, Jan S, Matthews GM: Subtilisin-related serine proteases in the mammalian constitutive secretory pathway. Cell Dev Biol 1998;9: 11-17.
Seidah NG, Chrétien M, Day R: The family of subtilisin/kexin like pro-protein and pro-hormone convertases: Divergent or shared functions. Biochimie 1994;76:207-209.
Montgomery AMP, DeClerck YA, Langley KE, Reisfeld RA, Mueller BM: Melanoma-mediated dissolution of extracellular matrix: Contribution of urokinase-dependent and metalloproteinase-dependent proteolytic pathways. Cancer Res 1993; 53:693-700.
Santavicca M, Noël A, Stoll I, Segain JP, Angliker H, Anglard P, Chrétien M, Seidah N, Bassel P: Characterisation of structural determinants and molecular mechanisms involved in stromelysin-3 activation by 4-aminophenylmercuric acetate and furin-type convertases. Biochem J 1996;315:953-958.
Maquoi E, Noël A, Frankenne F, Angliker H, Murphy G, Foidart JM: Inhibition of matrix metalloproteinase 2 maturation and HT1080 invasiveness by a synthetic furin inhibitor. FEBS Lett 1998;424:262-266.
Carmeliet P, Moons L, Lijnen R, Baes M, Eemaître V, Tipping P, Drew A, Eeckhout Y, Shapito S, Lupu F, Collen D: Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 1997;17:439-444.
Baramova EN, Bajou K, Remacle A, L'Hoir C, Krell HW, Weidle UH, Noël A, Foidart JM: Involvement of PA/Plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Lett 1997;405:157-162.
Devy L, Noël A, Baramova E, Bajou K, Trentesaux C, Jardillier JC, Foidart JM, Jeannesson P: Production and activation of matrix metalloprotease-9 (MMP-9) by HL-60 promyelocytic leukemia cells. Biochem Biophys Res Commun 1997;238: 842-846.
Zhang Z, Winyard PG, Chidwick K, Murphy G, Wardell M, Carrel RW, Blake DR: Proteolysis of human native and oxidised alpha 1-proteinase inhibitor by matrilysin and stromelysin. Biochim Biophys Acta 1994; 19:224-228.
Sires UI, Murphy G, Baragi VM, Fliszar CJ, Welgus HG, Senior RM: Matrilysin is much more efficient than other matrix metalloproteinases in the proteolytic inactivation of α1-antitrypsin. Biochem Biophys Res Commun 1994;204:613-620.
Noël A, Santavicca M, Stoll I, L'Hoir C, Staub A, Murphy G, Rio MC, Basset P: Identification of structural determinants controlling human and mouse stromelysin-3 proteolytic activities. J Biol Chem 1995;270:22866-22872.
Wolsberg TG, White JM: ADAMs in fertilization and development. Dev Biol 1996;180:389-401.
Wu E, Croucher PI, McKie N: Expression of members of the novel membrane linked metalloproteinase family ADAM in cells derived from a range of haematological malignancies. Biochem Biophys Res Commun 1997;235:437-442.
Blobel CP: Metalloprotease-disintegrins: Link to cell adhesion and cleavage of TNF alpha and Notch. Cell 1997;90:589-592.
Millichip MI, Dallas DJ, Wu E, Dale S, McKie N: The metallo-disintegrin ADAM10 (MADM) from bovine kidney has type IV collagenase activity in vitro. Biochem Biophys Res Commun 1998;245:594-598.
Rosendahl MS, Ko SC, Long DL, Brewer MT, Rosenzweig B, Hedl E, Anderson L, Pyle SM, Moreland J, Meyers MA, Kohno T, Lyons D, Lichtenstein HS: Identification and characterization of a pro-tumor necrosis factor-a-processing enzyme from the ADAM family zinc metalloproteases. J Biol Chem 1997;272: 24588-24593.
Liotta LA: Cancer cell invasion and metastasis. Sci Am 1992;266:34-41.
Opdenakker G, Van Damme J: Cytokines and proteases in invasive processes: Molecular similarities between inflammation and cancer. Cytokines 1992;4:35-40.
Nawrocki B, Polette M, Marchand V, Maquoi E, Beorchia A, Tournier JM, Foidart JM, Birembaut P: Membrane-type matrix metalloproteinase-1 expression at the site of human placentation. Placenta 1996; 17:565-572.
Maquoi E, Polette M, Nawrocki B, Bischof P, Noël A, Pintiaux A, Santavicca M, Schaaps JP, Pijnenborg P, Biremhaut P, Foidart JM: Expression of stromelysin-3 in the human placenta and plancental bed. Placenta 1997;18:277-285.
Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980; 284:67-68.
MacDougall JR, Matrisian LM: Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev 1995;14: 351-362.
Stetler-Stevenson WG, Hewitt R, Corcoran M: Matrix metalloproteinases and tumor invasion: From correlation and causality to the clinic. Cancer Biol 1996;7:147-154.
Coussens LM, Werb Z: Matrix metalloproteinases and development of cancer. Chem Biol 1996;3:895-904.
Yu AE, Hewitt RE, Kleiner DE, Stetler-Stevenson WG: Molecular regulation of cellular invasion-role of gelatinase A and TIMP-2. Biochem Cell Biol 1996;74:823-831.
Polette M, Gilbert N, Stas I, Nawrocki B, Noël A, Remacle A, Stetler-Stevenson WG, Birembaut P, Foidart JM: Gelatinase A expression and localization in human breast cancers. An in situ hybridization study and immunohistochemical detection using confocal microscopy. Virchows Archiv 1994;424: 641-645.
Schnack-Nielsen B, Sehested M, Timshel S, Pyke C, Dano K: Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. Lab Invest 1996;74:168-177.
Schnack-Nielsen B, Sehested M, Kjeldsen L, Borregaard N, Rygaard J, Dano K: Expression of matrix metalloproteinase-9 in vascular pericytes in human breast cancer. Lab Invest 1997;77:345-355.
Noël A, Polette M, Lewalle JM, Munaut C, Emonard H, Birembaut P, Foidart JM: Coordinate enhancement of gelatinase A mRNA and activity levels in human fibroblasts in response to breast adenocarcinoma cells. Int J Cancer 1994;56:331-336.
Ito A, Nakajima S, Sasaguri Y, Nagase H, Mori Y: Co-culture of human breast adenocarcinoma MCF-7 cells and human dermal fibroblasts enhances the production of matrix metalloproteinases 1, 2 and 3 in fibroblasts. Br J Cancer 1995;71: 1039-1045.
Chambers AF, Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89:1260-1270.
D'Armiento J, DiColandrea T, Dalal SS, Okada Y, Huang MT, Conney AH: Collagenase expression in transgenic mouse skin causes hyperkeratosis and acanthosis and increases susceptibility to tumorigenesis. Mol Cell Biol 1995;15:5732-5739.
Sympson CJ, Bissel MJ, Werb Z: Mammary gland tumor formation in transgenic mice overexpressing stromelysin-1. Semin Cancer Biol 1995;6:159-163.
Witty JP, McDonnell S, Newell K, Canon P, Navre M, Tressler R, Matrisian LM: Modulation of matrilysin levels in colon carcinoma cell lines affects tumorigenicity in vivo. Cancer Res 1994;54:4805-4812.
Noël A, Lefèbvre O, Maquoi E, Vanhoorde L, Chenard MP, Mareel M, Foidart JM, Basset P, Rio MC: Stromelysin-3 expression promote tumor taken in nude mice. J Clin Invest 1996;97:1924-1930.
Montgomery AM, Mueller BM, Reisfeld RA, Taylor SM, DeClerck YA: Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. Cancer Res 1994;54:5467-5473.
DeClerck YA, Perez N, Shimada H, Boone TC, Langley KE, Taylor SM: Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 1992;52:701-708.
Imren S, Kohn DB, Shimada H, Blavier L, DeClerck YA: Overexpression of tissue inhibitor of metalloproteinases-2 by retroviral mediated gene transfer in vivo inhibits tumor growth and invasion. Cancer Res 1996;56:2891-2895.
Sledge GW, Qulali M, Goulet R, Bone EA, Fife R: Effect of matrix metalloproteinase inhibitor Batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst 1995;87:1546-1550.
Talbot DC, Brown PD: Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur J Cancer 1996;32A:2528-2533.
Noël A, Hajitou A, L'Hoir C, Maquoi E, Baramova E, Lewalle JM, Remade A, Kebers F, Brown P, Calberg-Bacq CM, Foidart JM: Inhibition of stromal matrix metalloproteases: Effects on breast-tumor promotion by fibroblasts. Int J Cancer 1998;76:267-273.
Whitelock JM, Murdoch AD, Iozzo RV, Underwood PA: The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem 1996; 271:10079-10086.
Noël A, De Pauw-Gillet MC, Purnell G, Nusgens B, Lapière CM, Foidart JM: Enhancement of tumorigenicity of human breast adenocarcinoma cells in nude mice by matrigel and fibroblasts. Br J Cancer 1993; 68:909-915.
Yamaguchi Y, Mann DM, Ruoslahti E: Negative regulation of transforming growth factor-β by the proteoglycan decorin. Nature 1990;346: 281-284.
Plouët J, Moro F, Bertagnolli S, Coldebœuf N, Mazarguil H, Clamens S, Bayard F: Extracellular cleavage of the vascular endothelial growth factor 189-amino form by urokinase is required for its mitogenic effect. J Biol Chem 1997;272:13390-13396.
Manes S, Mira E, del Mar Barbacid M, Cipres A, Fernandez-Resa P, Buesa JM, Mérida I, Aracil M, Marquez G, Martinez-A C: Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3. J Biol Chem 1997; 272:25706-25712.
Collett-Solberg PF, Cohen P: The role of the insulin-like growth factor binding proteins and the IGFBP proteases in modulating IGF action. Endocrinol Metab Clin North Am 1996;25:591-614.
Oh Y: IGF-independent regulation of breast cancer growth by IGF binding proteins. Breast Cancer Res Treat 1998;47:283-293.
Roskelley CD, Srebrow A, Bissell MJ: A hierarchy of ECM-mediated signalling regulates tissue-specific gene expression. Curr Opin Cell Biol 1995;7:736-747.
Weaver VM, Fischer AH, Peterson OW, Bissell MJ: The importance of the microenvironment in breast cancer progression: Recapitulation of mammary tumorigenesis using a unique human mammary epithelial cell model and a three-dimensional culture assay. Biochem Cell Biol 1997;74:833-851.
Boudreau N, Sympson CJ, Werb Z, Bissell MJ: Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science 1995;267:891-893.
Brooks PC, Montgomery AMP, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA: Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79:1157-1164.
Montgomery AMP, Reisfeld RA, Cheresh DA: Integrin IvJ3 rescues melanoma cells from apoptosis in a three-dimensional dermal collagen. Proc Natl Acad Sci USA 1994;91: 8856-8860.
Sympson CJ, Talhouk RS, Alexander CM, Chin JR, Clift SM, Bissell MJ, Werb Z: Targeted expression of stromelysin-1 in mammary gland provides evidence for a role of proteinases in branching morphogenesis and the requirement for an intact basement membrane for tissue-specific gene expression. J Cell Biol 1994;125:681-693.
Witty JP, Wright JH, Matrisian LM: Matrix metalloproteinases are expressed during ductal and alveolar mammary morphogenesis, and misregulation of stromelysin-1 in transgenic mice induces unscheduled alveolar development. Mol Biol Cell 1995;6:1287-1303.
Weaver VM, Petersen OW, Wang F, Larabell CA, Briand P, Damsky C, Bissell MJ: Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol 1997;137:231-245.
Hulboy DL, Rudolph LA, Matrisian LM: Matrix metalloproteinases as mediators of reproductive function. Hum Reprod 1997;3:27-45.
Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364.
Hu G-F, Riordan JF, Vallee BL: Angiogenin promotes invasiveness of cultured endothelial cells by stimulation of cell-associated proteolytic activities. Proc Natl Acad Sci USA 1994;91:12096-12100.
Kakeji Y, Teicher BA: Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest New Drugs 1997;15: 39-48.
Schnaper HW, Grant DS, Stetler-Stevenson WG, Fridman R, D'Orazi G, Murphy A, Bird RE, Hoyhtya M, Fuerst TR, Quigley J, French D, Kleinman H: Type IV collagenases and TIMPs modulate endothelial cell morphogenesis in vitro. J Cell Physiol 1993;156:235-246.
Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S: Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998;58:1048-1051.
Brooks PC, Stromblad S, Sanders LC, Von Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP, Cheresh DA: Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with αvβ3. Cell 1996;85:683-693.
Brooks PC, Silletti S, von Schalscha TL, Friedlander M, Cheresh DA: Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 1998;92:391-400.
Schnaper WH, Barnathan ES, Mazar A, Maheshwari S, Ellis S, Cortez SL, Baricos WH, Kleinman HK: Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways. J Cell Physiol 1995;165:107-118.
Bajou K, Noël A, Gerard RD, Brunner N, Holst-Hansen C, Skobe M, Fusenig N, Carmeliet P, Collen D, Foidard JM: Absence of host plasminogen activator inhibitor-1 prevents cancer invasion and vascularization. Nat Med 1998;4:923-928.
O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane W, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-285.
Dong Z, Kumar R, Yang X, Fidler IJ: Macrophae-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 1997;88:801-810.
Patterson BC, QingXiang AS: Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J Biol Chem 1997;272: 28823-28825.
Blasi F: uPA, uPAR, PAI-1: Key intersection of proteolytic, adhesive and chemotactic highways? Immunol Today 1997;18:415-417.
Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ: Is plasminogen activator-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 1996;134:1563-1571.
Edwards DR, Murphy G: Proteases-invasion and more. Nature 1998;394:527-528.
Basbaum CB, Werb Z: Focalized proteolysis: Spatial and temporal regulation of extracellular matrix degradation at the cell surface. Curr Opin Cell Biol 1996;8:731-738.
Preece G, Murphy G, Ager A: Metalloproteinase-mediated regulation of L-selectin levels on leucocytes. J Biol Chem 1996;271: 11634-11640.
Arribas J, Lavanya C, Vollmer P, Kishimoto TK, Rose-John S, Massagué J: Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors. J Biol Chem 1996;271: 11376-11382.
Bracke ME, Van Roy FM, Mareel MM: The E-cadherin/catenin complex in invasion and metastasis. Curr Top Microbiol Immunol 1996;213:123-161.
Lochter A, Galosy S, Muschler J, Freedman N, Werb Z, Bissell MJ: Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and premalignant phenotype in mammary epithelial cells. J Cell Biol 1997;139:1861-1872.
Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B, Clevers H: Constitutive transcriptional activation by a β-catenin-Tcf complex in APC-/-colon carcinoma. Science 1997;275:1784-1787.
